<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences has filed its yearly disclosure required under a SEBI circular that applies to companies classified as 'Large Corporates.' The company has confirmed that it does NOT fall under the Large Corporate category based on the criteria in the SEBI circular dated 26 November 2018. As on 31 March 2025, the company's outstanding long-term borrowings (excluding ECB) stood at ₹22.93 crore, which is below the threshold. The company's highest credit rating during the previous financial year was 'BBB+ with Stable outlook' from CARE Ratings. The disclosure was signed by the Company Secretary and CFO on 4 April 2025.
This is a routine regulatory compliance filing with no material impact on shareholders or stock price. It simply confirms the company's modest debt levels (₹22.93 crore) and investment-grade credit rating, meaning Hester is not obligated to meet the mandatory minimum borrowing or fines framework that applies to Large Corporates.